echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > How does the biomedical industrial park develop?

    How does the biomedical industrial park develop?

    • Last Update: 2022-01-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    This issue of "Analysis of Development Models of Foreign Biomedical Parks" focuses on the analysis of the development models of biomedical parks in the United States, the United Kingdom, France, Japan, Singapore and other regions, and summarizes the key common features in the successful development of foreign biomedical parks.
    The operation of Hetao International Biomedical Industrial Park can be used for reference
    .
    From the distribution map of the world's biopharmaceutical industry, North America, Europe, and Japan are the three most highly developed regions in the global biopharmaceutical industry
    .
    In recent years, the close cooperation network of biotechnology, pharmaceutical companies and academic institutions has made the biomedical market in the United States and Europe active, and the relevant system in the United States is the most complete
    .
    In the current development environment of the pharmaceutical industry, the United States is in a leading position in the world, whether in the development of traditional chemical pharmaceuticals or new biopharmaceuticals, or in terms of industrial scale and market share
    .
    The United States has the most advanced biopharmaceutical industry clusters and R&D institutions, and the most important thing is that it has the most biotechnology patents.
    The number of new products developed by its biopharmaceutical industry and its market share have reached more than 80%.
    The number of biotechnology patents is Nearly 40 of the world's top 50 biopharmaceutical companies account for half of the world's total.
    Therefore, the United States has almost monopolized the new biotechnology drugs on the market.
    The following points are the reasons
    .
    1.
    Significant scale effect of agglomeration On June 4th, in order to further meet the needs of the corporate public to inquire about medical device regulatory information, and to strengthen social supervision and social co-governance, the State Food and Drug Administration summarized the data of all provinces (autonomous regions and municipalities directly under the Central Government as of May 31) ) within the validity period of medical device product registration and filing, medical device manufacturing enterprise license filing, medical device operating enterprise license filing, medical device online sales filing, and medical device online transaction service third-party platform filing information
    .
    Among them, the top three in the number of domestic medical device product registration certificates are Jiangsu, Guangdong, and Beijing, and the top three in the number of filing certificates are Jiangsu, Guangdong, and Shandong
    .
    The United States has always been known for the scale of the biopharmaceutical industry.
    It is the most important agglomeration area for the industry and has the largest number of multinational pharmaceutical companies in the world.
    Among them, Pfizer, Johnson & Johnson, Abbott, Merck, etc.
    are all world-class pharmaceutical companies.

    .
    The formation of this highly concentrated pharmaceutical industry cluster in space is an important feature of the development of biomedicine in the United States
    .
    Boston's "Gene City" and San Francisco Bay's "Biotech Bay" are the biomedical industry clusters with the highest degree of industrialization and the most active innovation in the world
    .
    There are 51 metropolitan business districts in the United States, and 75% of the biomedical industry resources are concentrated in 9 of them, including Boston, Philadelphia, New York, San Diego, Seattle, and San Francisco
    .
    These nine metropolitan business circles are home to nearly nine times as many biotech companies as other regions
    .
    This high-quality biopharmaceutical industry agglomeration must attract a large number of research talents and high-level venture capital
    .
    2.
    Pay attention to the contribution of basic research Basic research is defined as follows: without any special purpose and application as the premise, actively carry out experimental and theoretical work to obtain relevant principles and knowledge of relevant phenomena and observable facts
    .
    Essentially, basic research is a reserve of new knowledge and scientific capital invested in the future.
    The development of any new technology and new product must be based on basic research
    .
    Not only that, the cultivation of professional talents also depends on basic research
    .
    Scientific research institutions and universities are the main bases for basic research
    .
    The biopharmaceutical industry in the United States is built on the basis of academic research institutions
    .
    For example, the biomedical industry cluster in Boston was developed on the basis of top universities and scientific research institutions such as Harvard University, Boston University, and Mass General Hospital
    .
    In recent decades, the United States has been at the world's leading level in the research of chemistry, biology and other disciplines.
    The development of these basic researches determines that the related biomedical industry must be at the forefront of the world, leading the trend of the world's biomedical industry
    .
    In addition to efficient basic research, universities and scientific research institutions are also nurturing places for high-quality talents.
    A large number of master and doctoral students focusing on basic research have sprung up like mushrooms after a spring rain, bringing fresh blood to the development of the biopharmaceutical industry.

    .
    3.
    R&D and venture capital capabilities On June 4th, in order to further meet the needs of the corporate public to inquire about medical device regulatory information, and to strengthen social supervision and social co-governance, the State Food and Drug Administration summarized the data of all provinces (autonomous regions, autonomous regions, and autonomous regions) as of May 31.
    Municipalities) within the validity period of medical device product registration and filing, medical device manufacturing enterprise license filing, medical device operating enterprise license filing, medical device online sales filing, and medical device online transaction service third-party platform filing information
    .
    Among them, the top three in the number of domestic medical device product registration certificates are Jiangsu, Guangdong, and Beijing, and the top three in the number of filing certificates are Jiangsu, Guangdong, and Shandong
    .
    The United States has maintained high investment in the biomedical industry, which is largely due to its sound venture capital network
    .
    As we all know, the biopharmaceutical industry needs innovation, and the research and development costs of new drugs are high, the research and development cycle is long, and the research and development results are uncertain.
    investment
    .
    At present, the development of many biopharmaceutical industries focuses on scientists and venture capital
    .
    Although scientists have strong research and development capabilities and can provide technical support, funding is an indispensable guarantee for their research, and American venture capital companies are willing to invest a lot of money in the biomedical industry with better development prospects, so that scientists can Combining these two aspects with venture capital will jointly promote the development of the biomedical industry
    .
    To sum up, the well-established venture capital network in the United States has brought a high level of R&D investment, which has helped the development of the US biopharmaceutical industry
    .
    The United Kingdom, Germany, France and other European countries have also actively adopted supportive policies in the development of biotechnology parks, using their strong scientific research foundation to establish a scientific research and technological innovation network, and cultivate a large number of dynamic small and medium-sized technology enterprises; Japan, Singapore and other Asian countries The country has also made full use of the large investment of the government and the advantages of high-quality biomedical talents and research institutions.
    In the planning of the biomedical park, efforts are made to explore the development path of the park that is suitable for the national conditions and the regional economy.

    .
    Introduction to the development of biomedical parks in other countries and regions In summary, foreign biomedical parks have a good innovation network and innovation culture
    .
    The common elements of its successful development are as follows: (1) The biomedical park aims to condense the resources of universities, scientific research institutions and the biomedical industry, and promote local economic development; (2) The park has obvious location advantages, strong independent research and development capabilities, and high conversion rate of scientific research and technological achievements; ③The park has a relatively complete social service system; ④It pays attention to internal and external cooperation, attracting venture capital enterprises and industrial funds to help the development of the park
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.